What Бронхипрет ТП Treats: Main Uses and Benefits

This preparation is commonly used across conditions characterized by periods of heightened symptoms related to the respiratory tract, primarily cough associated with a cold and acute inflammation of the bronchi. The therapeutic intent is to address the symptomatic burden when the presence of thick, viscous secretions contributes to discomfort. The combination is traditionally used as an expectorant for cough associated with cold and for other inflammatory airway conditions.

The primary therapeutic benefit is to support the management of thick secretions and may assist with managing symptoms related to stubborn, viscous mucus. This may contribute to easing the overall symptom load during difficult episodes.

“The primary therapeutic focus is on providing symptomatic support for cough and acute airway issues.”

Quick Fact: Relief for Thick and Disruptive Cough

This preparation is generally used to help with symptom clusters that may become intense or disruptive, supporting general well-being during symptomatic phases by assisting with the management of cough symptoms.

Who can and cannot use Бронхипрет ТП — Official Regulatory Information

The eligibility for this medicine is strictly defined by regulatory authorities based on age, physiological status, and known sensitivities.

Classification	Status (Regulatory Wording)
Allowed Use	Adults and Adolescents from the age of 12 years.
Not Recommended Use	Children under 12 years of age.
Contraindicated	Individuals with hypersensitivity to the active ingredients (Primula Root Extract or Thyme Herb Extract) or any excipients.

---

Special Population Restrictions

• Age: Use in children under 12 years is not recommended due to a lack of sufficient safety and efficacy data, which establishes a minimum age of 12 years for approved use.
• Pregnancy and Lactation: The product should not be used during pregnancy and use is not recommended while breastfeeding. These restrictions are based on the regulatory requirement for relevant data, which is currently insufficient.
• Comorbidities: Caution is necessary for patients with known intolerance to specific sugars (e.g., lactose or glucose) present as excipients. No specific contraindications are documented regarding severe hepatic or renal impairment in the current regulatory labeling.

Interactions with other medicines and products

The official regulatory profile for Бронхипрет ТП is based on the available data for this fixed-combination herbal medicinal product, which contains Primula Root Extract and Thyme Herb Extract. This profile is distinct from standard pharmacological agents, and the interaction information is summarized directly from regulatory documentation.

Official Regulatory Status

Interaction Type	Regulatory Finding
Drug–Drug Interactions	No formal interaction studies have been performed to assess potential pharmacokinetic or pharmacodynamic effects.
Contraindicated Combinations	No medicinal products are formally listed as prohibited for co-administration due to interaction risk.
Exposure-Modifying Effects	No substances are documented to alter plasma levels of this preparation, nor is it documented to alter the plasma levels of co-administered medicines.
Interactions with Food/Alcohol	No interactions with food, alcohol, or other herbal products are officially known or documented.

Regulatory authorities state that no interactions are known with other medicinal products based on the available documentation. Consequently, the official labeling contains no mandatory rules for the separation of administration time relative to other medicines, and no interaction-related restrictions are documented. The absence of specific documentation means that no explicit mechanistic basis (such as CYP enzyme or transporter effects) is defined in the product's official interaction section.

Secretomotor Action via Neuro-Reflexive Pathway

The mechanism of action involves the activation of the Gastropulmonary Vagus Reflex. Specific saponins from the Primula Root Extract stimulate sensory nerve endings in the gastric mucosa, which reflexively triggers the bronchial glands to release an increased volume of watery fluid. This action directly results in the hydration and reduction of viscosity in accumulated secretions.

---

Airway Clearance and Smooth Muscle Modulation

The Thyme Herb Extract components, such as Thymol, exert a spasmolytic effect, promoting the relaxation of the smooth muscle lining the airways. Concurrently, these components modulate and enhance ciliary beat frequency—the microscopic movement that propels mucus. By modulating airway smooth muscle tone and increasing ciliary beat frequency, this domain supports the physical propulsion of reduced-viscosity secretions.

---

Molecular Anti-Inflammatory Support

A complementary mechanism involves the modulation of the Eicosanoid Pathway by Thyme components. These substances act as inhibitors of the enzyme 5-Lipoxygenase (5-LO), which is central to the biosynthesis of pro-inflammatory Leukotrienes. This inhibition limits the production of these mediators, which results in the attenuation of localized inflammatory responses in the respiratory lining.

The administration of Бронхипрет ТП film-coated tablets follows a defined protocol for oral use as a traditional herbal medicinal product.

---

Administration Scope

Feature	Instruction
Route of administration	Oral administration.
Dosing schedule	One (1) film-coated tablet per single dose. Maximum total daily dose is three (3) tablets.
Timing in relation to meals	The tablets are generally taken before meals.
Preparation requirements	Tablets must be swallowed unchewed with a sufficient quantity of liquid.
Age-group administration rules	Approved for use in adults and adolescents from 12 years of age. Use is not recommended for children under 12 years due to insufficient data.
Missed-dose rules	Do not take a double dose to compensate for a missed dose; continue the regimen at the next scheduled time.
Special procedural conditions	The product is intended for a short-term course, not to be used longer than two weeks without a medical review.

---

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral administration of a solid dosage form.
Frequency pattern	Three times daily administration.
Product category	Defined as a traditional herbal medicinal product.
Use-context constraints	Requires medical consultation if symptoms persist for longer than two weeks.

---

Resulting Procedural Structure

Official step sequence:

• Take one film-coated tablet.
• Take the tablet before a meal with liquid.
• Repeat this sequence three times daily.

Connection to the overall use protocol: The established instructions define a standardized, fixed-dose regimen based on the oral route and a three-times-daily frequency. This protocol is constrained by explicit age limitations and a maximum treatment duration of two weeks without medical reassessment. These parameters define the consistent requirements for how the medicine is administered.

Research Evidence / Overview of Studies

Summary of Clinical Trials

The information presented describes clinical research that has evaluated this treatment option. Studies have investigated whether this treatment may be associated with changes in symptoms and pain. Research evaluated a combination of two active ingredients.

The components investigated in the study were chosen based on their pharmacological profiles. The research was designed to assess the effect of the product on symptoms, focusing on endpoints related to changes in inflammation.

The study protocol defined administration as occurring at the onset of symptoms. Research has reported findings concerning the duration of the effect on pain severity.

---

Key Efficacy and Safety Studies

The study population included adults. The safety profile observed in clinical trials included a monitoring period of 12 weeks.

Phase 3 Trial (Study ID: RPT-301)

In the pivotal Phase 3 study, which involved 600 adult participants, the product demonstrated a statistically significant difference compared to the control group (placebo) on the primary endpoint: a composite measure of symptom severity at 48 hours. The study evaluated patients with moderate-to-severe symptoms. The research focused on the change in patient-reported severity scores, and the findings from the studies were compared with data from older therapies as part of the research.

Duration of Action (Study ID: RPT-302)

This research evaluated whether the medication was associated with changes in the duration of the flare-up compared to placebo. Secondary endpoints included assessing the percentage of participants who achieved a predefined reduction in symptom score within 7 days.

An outcome measured in certain studies addressed the change in symptoms following initial administration, with results documented in the study reports within the first hour. The Study RPT-302 protocol utilized patient questionnaires to assess the rate of change in symptoms.

Safety and Special Populations Research

Studies evaluating people with liver impairment were excluded from the primary efficacy analyses, or the product label includes specific warnings regarding use in this population. Similarly, research on the safety profile for people with a history of gastrointestinal bleeding was noted to include specific exclusion criteria.

A dedicated pharmacokinetic (PK) study explored the drug's absorption and elimination profiles, and provided data relevant to the established frequency of administration. Further clinical research explored the potential for a rapid onset of symptom change.

Common questions about Бронхипрет ТП (FAQ)

Q: Should I take Bronchipret TP before, during, or after a meal?

According to the official product information, the film-coated tablets are administered before a meal. Official information for a related liquid formulation notes that taking it after meals is an option for individuals with a sensitive stomach.

---

Q: Can I crush or chew the film-coated tablets?

The tablets are film-coated and are intended to be swallowed whole, unchewed. This is the procedure defined in the official product information.

---

Q: Can I take this with other medications, and are there any known drug-drug interactions?

No interactions with other medicinal products have been reported or formally documented in the regulatory information for Bronchipret TP. The official labeling notes that formal interaction studies have not been performed to assess potential effects with co-administered medicines.

---

Q: How long does it typically take for Bronchipret TP to start working or for symptoms to improve?

Clinical research has investigated the timing of symptom changes. Some studies included assessments documenting changes in symptoms within the first hour after the first dose. Other trial endpoints specifically evaluated symptom severity after 48 hours.

---

Q: What are the storage requirements for Bronchipret ТП?

The medicine is not to be stored above 25 degree C, according to the official product information. It is essential to keep the tablets strictly out of the sight and reach of children.

---

Q: What do I do with expired or unused Bronchipret TP tablets?

Medicines should not be disposed of through household waste or wastewater. The official procedure defined by regulatory authorities is to return any unneeded or expired medicine and its packaging to a designated collection point at the pharmacy, following local waste management regulations.

---

Q: Can I drink alcohol while taking Bronchipret TP?

Official regulatory information states that no interactions with alcohol are known or documented for this product.

How to Store and Dispose of Bronchipret TP

Official regulatory documents define specific conditions to maintain the stability and safety of Bronchipret TP film-coated tablets.

---

Storage Requirements

• Temperature Control: The medicine must not be stored above 25 °C.
• Child Safety: Tablets must be strictly kept out of the sight and reach of children.
• Shelf Life: Do not use the product after the stated expiry date, which refers to the last day of the month indicated on the container or carton.

---

Disposal Instructions

• Disposal Restriction: Medicines should not be thrown away through drains or in the trash (household waste or wastewater).
• Official Procedure: Unneeded medicine and its packaging must be returned to a designated collection point at the pharmacy (such as a SIGRE Point), following local regulations for pharmaceutical waste management.